Biotech company Aimmune has announced plans to file its potential peanut allergy treatment at the end of the year following its major phase 3 trial success. Aimmune saw its shares surge last month ...

Almost exactly three years after agreeing on a $2.6 billion deal to acquire Aimmune Therapeutics and its peanut allergy therapy Palforzia, food group Nestle has sold off the business. This morning ...

Chinook was acquired by Novartis AG. Prior to Chinook, Mr. Bjerkholt was CFO of Aimmune Therapeutics, which was acquired by Nestle Health Science. Previously Mr. Bjerkholt worked at Sunesis ...